Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum -resistant ovarian cancer.
Ovarian Cancer
DRUG: Hycamptin|DRUG: Gemcitabine
Determine the maximum tolerated dose and the response rate of gemcitabine plus topotecan., 1year
Toxicity profile, 1 year
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum -resistant ovarian cancer.